Project Grant HT94252510842
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$661K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14611, USA
Similar Awards
This federal Project Grant award for $1,173,575.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Rochester to develop an "Anticodon-Edited (ACE) tRNA Treatment of Nonsense-Mediated Duchenne Muscular Dystrophy". The research aims to investigate innovative treatments for Duchenne muscular dystrophy, a debilitating genetic disorder primarily affecting military service members and veterans. The award,...
The University of Rochester was awarded a $1,875,712 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First 3 Years in Children with Duchenne Muscular Dystrophy", will support advanced biomedical research to investigate medical solutions for Duchenne muscular dystrophy, a rare genetic disorder. The grant has a...
The University of Rochester received a $812,602 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "IMAGING CANCER MICROENVIRONMENT HOT SPOTS INVOLVED IN PROGRESSION OF MYELODYSPLASTIC SYNDROMES." The research, which will take place from May 2024 to May 2027, aims to improve understanding of the cancer microenvironment and its role in the progression of myelodysplastic syndromes, a group of...
This federal Project Grant award of $513,653.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by the University of Arkansas to develop self-delivering gene editors for the correction of Duchenne muscular dystrophy. The award period runs from August 15, 2024 to August 14, 2026, and aligns with the program's goal of transforming healthcare for military service members and the broader public through innovative...
The University of Rochester received a $769,996 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct spinal cord injury research. The 3-year award, which began on September 1, 2024, will support the University of Rochester's investigator-initiated research on spinal cord injuries. Through this federal grant, the university will deliver scientific research and studies to advance medical treatments and care for...
This $539,400 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports vascular targeted therapy research for Duchenne muscular dystrophy. The grant was awarded to the Regents of the University of Minnesota, a major land-grant research university, to conduct this cutting-edge biomedical research project. The research aims to develop new treatments and advance scientific understanding of this neurological disorder, which...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
This federal Project Grant award of $345,664.00 from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, supports an advanced biomedical research initiative led by Royal Holloway University of London. The research project aims to develop an AAV-based microdystrophin gene therapy for Duchenne muscular dystrophy, with a focus on enhancing immune protection through capsid bioengineering. The award period spans from December 1, 2024 to November 30,...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program provides $154,000.00 to the University of Rochester to conduct research on NETRIN-1 as a druggable driver of pancreatic neuroendocrine tumor metastasis. The project will run from November 1, 2024 to October 31, 2025. As a leading research university with extensive federal research capabilities, the University of Rochester will leverage its expertise...
This Project Grant award in the amount of $308,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Rochester. The grant is funding a research project to investigate "INVESTIGATING MICROGLIAL REMODELING OF NEURAL CIRCUITS IN PREGNANCY" over a 2-year period from November 15, 2023 to November 14, 2025. The project aims to advance scientific understanding of the role of microglia, a type of immune...